Innovation in environmental sustainability: leading companies in antimalarial compositions

Innovation in environmental sustainability: leading companies in antimalarial compositions

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by changing treatment paradigms, the severity of unmet medical needs, as well as the growing importance of topics such as pharmacogenomics, digital therapeutics and artificial intelligence. In the past three years alone, more than 633,000 patents have been filed and granted in the pharmaceutical industry, according to GlobalData’s Environmental Sustainability in Pharmaceuticals: Antimalarial Compositions report.

According to GlobalData’s Technology Foresights, which uses more than 756,000 patents to analyze the intensity of innovation for the pharmaceutical industry, there are 110 areas of innovation that will shape the future of the industry.

Antimalarial compositions are a key area of ​​innovation in environmental sustainability

Antimalarial drugs such as chloroquine are used for the treatment and prevention of malaria infection. The majority of antimalarial drugs focus on the erythrocytic stage of the disease which results in the symptoms of malaria. Antimalarial drugs work by killing the parasite – known as Plasmodium parasites – that has infected the patient’s red blood cells. There are several antimalarial drugs with various chemical structures, each damaging the disease-causing parasite in a different way, but usually by killing the parasite’s enzymes or activities in infected erythrocytes.

GlobalData’s analysis also reveals which companies are at the forefront of each area of ​​innovation and assesses the potential reach and impact of their patenting activity in different applications and geographies. According to GlobalData, there are more than 30 companies, spanning technology providers, established pharmaceutical companies and promising start-ups engaged in the development and application of antimalarial compositions.

Key Players of Antimalarial Compounds – Breakthrough Innovation in Pharmaceutical Industry

“Application diversity” measures the number of different applications identified for each relevant patent and broadly divides companies into “niche” or “diversified” innovators.

“Geographical scope” refers to the number of different countries in which each relevant patent is registered and reflects the scope of intended geographical application, ranging from “global” to “local”.

GSK is a leading healthcare company focused on developing, manufacturing and marketing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, anticancer, immuno-inflammatory, antiviral, central nervous system (CNS), metabolic, cardiovascular and urogenital, antibacterial, dermatological and certain rare diseases. GSK and Medicines for Malaria Venture (MMV) have together developed a preclinical portfolio of antimalarial properties. Through its extensive global R&D and supply network, GSK offers clinical, regulatory and manufacturing knowledge and resources as compounds enter clinical development. In 2021, the WHO recommended wider use of GSK’s Mosquirix to reduce malaria illness and death in children living in sub-Saharan Africa and other areas with moderate to high transmission as defined by the WHO. WHO.

In terms of diversity of applications, CAS-Lamvac Biotech is the leading company followed by Theravectys and Vir Biotechnology. Thanks to its geographical reach, Theravectys ranks first. Otsuka Holdings and Regeneron Pharmaceuticals occupy the second and third positions respectively.

To better understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest Pharmaceutical Topic Research Report.

Related companies

#Innovation #environmental #sustainability #leading #companies #antimalarial #compositions

Leave a Comment

Your email address will not be published. Required fields are marked *